A.L. Wolf
Netherlands Cancer Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A.L. Wolf.
Radiotherapy and Oncology | 2013
A.C. Houweling; A.L. Wolf; Wouter V. Vogel; O. Hamming-Vrieze; Corine van Vliet-Vroegindeweij; Jeroen B. van de Kamer; Uulke A. van der Heide
PURPOSE The purpose of this study was to investigate if FDG-PET and DWI identify the same or different targets for dose escalation in the GTV of HN cancer patients. Additionally, the dose coverage of DWI-targets in an FDG-PET-based dose painting plan was analyzed. MATERIALS AND METHODS Eighteen HN cancer patients underwent FDG-PET and DWI exams, which were converted to standardized uptake value (SUV)- and apparent diffusion coefficient (ADC)-maps. The correspondence between the two imaging modalities was determined on a voxel-level using Spearmans correlation coefficient (ρ). Dose painting plans were optimized based on the 50% isocontour of the maximum SUV ( SUV(50%max)). Dose coverage was analyzed in three different SUV- and three different ADC-targets using the mean dose and the near-minimum and near-maximum doses. RESULTS The average maximum SUV was 13.9 and the mean ADC was 1.17 · 10(-3) mm(2)/s. The average ρ between SUV and ADC was -0.2 (range: -0.6 to 0.4). The ADC-targets were only partly overlapping the SUV(50%max)-target and the dose parameters were significantly smaller in the ADC-targets compared to the SUV(50%max)-target. CONCLUSIONS FDG-PET and DWI contain different information, resulting in different targets. Further information about failure patterns and dose relations can be obtained by adding DWI to currently ongoing dose painting trials.
International Journal of Radiation Oncology Biology Physics | 2015
Johan de Boer; A.L. Wolf; Yenny Z. Szeto; Marcel van Herk; Jan-Jakob Sonke
Radiotherapy and Oncology | 2013
A.L. Wolf; Emmy Lamers; S. van Kranen; O. Hamming-Vrieze; E. Damen; C. Van Vliet-Vroegindeweij
Radiotherapy and Oncology | 2017
T.M. Janssen; A. Dikstaal; M. Kwint; S. Marshall; A.L. Wolf; J. Knegjens; L. Moonen; J. Belderbos; J.J. Sonke; M. Verheij; C. Van Vliet-Vroegindeweij
Radiotherapy and Oncology | 2016
T.M. Janssen; A.L. Wolf; J. Knegjens; L. Moonen; J. Belderbos; J.J. Sonke; M. Verheij; C. Van Vliet-Vroegindeweij
Radiotherapy and Oncology | 2015
S. van Kranen; A.L. Wolf; O. Hamming-Vrieze; M. van Herk; J.J. Sonke
Radiotherapy and Oncology | 2014
M. Frantzen-Steneker; M. Helle; H. Schulz; Steffen Renisch; N. Schadewaldt; A.L. Wolf; R. Rozendaal; S. van Kranen; E. Alpay; U. Van der Heide
Radiotherapy and Oncology | 2014
R. De Graaf; R. Harmsen; A.L. Wolf; A. Olszewska; G. Retèl; C. Van Vliet-Vroegindeweij; E. Damen
Radiotherapy and Oncology | 2014
A.L. Wolf; A. Mans; C. Van Vliet-Vroegindeweij; E. Damen
Radiotherapy and Oncology | 2014
S. van Kranen; A.L. Wolf; S. van Beek; O. Hamming-Vrieze; M. van Herk; J.J. Sonke